GlobeNewswire Inc.Sep 8, 8:00 AM ETNeutral
Mentioned only as part of Kane's employment history; no new developments or direct impact on the company reported in this article.
Precision BioSciences news
$6.18−0.96%
Close Sep 29, 2026 · split-adjustedArticles · 30 days1English, de-duplicated
Positive00% of coverage
Neutral1100%
Negative00% of coverage
About Precision BioSciences
Also mentions DTIL
Articles that tag DTIL but are mainly about other companies.
GlobeNewswire Inc.Jul 3, 4:44 AM ETNeutral
Included in company profiles but without specific emphasis on competitive positioning or technological differentiation. Operates in growing market but lacks distinct competitive advantages mentioned in the article.
GlobeNewswire Inc.May 26, 1:00 PM ET▲ Positive
PBGENE-DMD received FDA Fast Track designation in March 2026 with Phase I/II FUNCTION-DMD study planned, indicating regulatory confidence in the gene therapy approach.
Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology